Lipella Pharmaceuticals Q1 2023 Earnings Report $3.14 -0.28 (-8.19%) As of 02/21/2025 04:00 PM Eastern Earnings HistoryForecast Lipella Pharmaceuticals EPS ResultsActual EPS-$1.52Consensus EPS N/ABeat/MissN/AOne Year Ago EPSN/ALipella Pharmaceuticals Revenue ResultsActual Revenue$0.12 millionExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/ALipella Pharmaceuticals Announcement DetailsQuarterQ1 2023Date5/15/2023TimeN/AConference Call ResourcesLIPO Earnings History Lipella Pharmaceuticals Earnings HeadlinesIDEAYA Biosciences (NASDAQ:IDYA) and Lipella Pharmaceuticals (NASDAQ:LIPO) Head-To-Head ReviewFebruary 19 at 2:07 AM | americanbankingnews.comLipella Pharmaceuticals Announces Positive Phase 2a Results for LP-310 in Oral Lichen Planus TreatmentFebruary 13, 2025 | americanbankingnews.comElon Takes Aim at Social SecurityElon Musk just dropped another bombshell... He revealed his DOGE organization has been taking aim at Social Security, finding what he says is widespread fraud across the agency.February 22, 2025 | Altimetry (Ad)Biotech Rips On Topline AnalysisFebruary 11, 2025 | msn.comLipella Pharmaceuticals reports ‘positive’ results from Phase 2a LP-310 trialFebruary 11, 2025 | markets.businessinsider.comLipella Pharmaceuticals Reports Positive Topline Phase 2a Results for LP-310 in the Treatment of Oral Lichen PlanusFebruary 11, 2025 | globenewswire.comSee More Lipella Pharmaceuticals Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Lipella Pharmaceuticals? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Lipella Pharmaceuticals and other key companies, straight to your email. Email Address About Lipella PharmaceuticalsLipella Pharmaceuticals (NASDAQ:LIPO), a biotechnology company, focuses on developing drugs by reformulating the active agents in existing generic drugs and optimizing these reformulations for various applications. The company develops LP-10, a formulation of tacrolimus that has completed Phase 2a clinical trial for patients with radiation-induced hemorrhagic cystitis; LP-310, a formulation of tacrolimus for the treatment of oral lichen planus; and LP-410, an oral liposomal formulation of tacrolimus for the treatment of oral graft-versus-host disease (GVHD). Lipella Pharmaceuticals Inc. was incorporated in 2005 and is headquartered in Pittsburgh, Pennsylvania.View Lipella Pharmaceuticals ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles The Trade Desk Crashes on Earnings, But Growth Catalysts PersistHims & Hers Earnings Could Be a Game Changer—What to Do NowAnalysts See Buying Opportunity in NVIDIA Before EarningsAirbnb's Earnings: Sky High Results, Grounded Guidance?Is Coinbase Stock a Buy After Earnings?CVS Health: Earnings Beat Ignites Stock RallyQualcomm’s Post-Earnings Dip: A Prime Buying Opportunity? Upcoming Earnings Workday (2/24/2025)Intuit (2/25/2025)American Tower (2/25/2025)Bank of Montreal (2/25/2025)Bank of Nova Scotia (2/25/2025)Public Storage (2/25/2025)NVIDIA (2/26/2025)Synopsys (2/26/2025)Salesforce (2/26/2025)Lowe's Companies (2/26/2025) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
